Literature DB >> 15844501

Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease.

Benedikt J Folz1, Julia Tennie, Burkard M Lippert, Jochen A Werner.   

Abstract

INTRODUCTION: Epistaxis is the most common symptom of a complex, genetically determined vasculopathy, which is known under the notion hereditary hemorrhagic telangiectasia (HHT, Rendu-Osler-Weber-syndrome). This study was initiated to gain more knowledge about the natural history of epistaxis in a German HHT-population. PATIENTS AND METHODS: Data of 49 HHT patients were ascertained by interviewing these patients with a standardized disease specific questionnaire. Patients' files were retrospectively reviewed for data concerning age, gender, past medical history, laboratory parameters, number of hospital admissions for epistaxis, conservative and operative types of therapy, treatment results and follow-up. MAIN RESULT: Epistaxis was the first and most prominent symptom in 93% of the patients and could be triggered most frequently by stress. Half of the patients had experienced first episodes of epistaxis in childhood, but usually epistaxis did not become troublesome before the age of 35 years. The effects of hormonal changes or therapies with systemic hormones were inconclusive with regard to impact on epistaxis. Patients with septal perforations had to be admitted for inpatient epistaxis treatment more frequently than patients with an intact nasal septum. An overall reduction of frequency and intensity of epistaxis could be achieved in 89% of the patients through the daily use of nasal lubricants and a minimum of two treatment sessions with the Nd:YAG laser. However in none of the cases the treatment results were permanent. More than 50% of the patients, who had been screened for visceral arteriovenous malformations, were positive for pathologic vascular lesions. PRINCIPAL
CONCLUSION: The natural history of epistaxis in German HHT patients is similar to previously described entities from other parts of the world. First clinical signs of HHT may be present at an earlier age than previously thought.

Entities:  

Mesh:

Year:  2005        PMID: 15844501

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  14 in total

Review 1.  [Current aspects in epistaxis].

Authors:  B J Folz; M Kanne; J A Werner
Journal:  HNO       Date:  2008-11       Impact factor: 1.284

2.  Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT).

Authors:  Kornelia E C Wirsching; Frank Haubner; Thomas S Kühnel
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-01-09       Impact factor: 2.503

Review 3.  Laser-Assisted Control of Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review.

Authors:  Arash Abiri; Khodayar Goshtasbi; Marlon Maducdoc; Ronald Sahyouni; Marilene B Wang; Edward C Kuan
Journal:  Lasers Surg Med       Date:  2019-08-22       Impact factor: 4.025

4.  ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.

Authors:  Sophie Dupuis-Girod; Alexis Ambrun; Evelyne Decullier; Géraldine Samson; Adeline Roux; Anne-Emmanuelle Fargeton; Catherine Rioufol; Verane Schwiertz; François Disant; François Chapuis; Yves Donazzolo; Gilles Paintaud; Patrick Edery; Frederic Faure
Journal:  MAbs       Date:  2014-01-30       Impact factor: 5.857

5.  Manifestations of hereditary hemorrhagic telangiectasia in children and adolescents.

Authors:  Benedikt J Folz; Barbara Zoll; Heiko Alfke; André Toussaint; Rolf F Maier; Jochen A Werner
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-06-24       Impact factor: 2.503

6.  Dietary supplement use and nosebleeds in hereditary haemorrhagic telangiectasia - an observational study.

Authors:  Basel Chamali; Helen Finnamore; Richard Manning; Michael A Laffan; Mary Hickson; Kevin Whelan; Claire L Shovlin
Journal:  Intractable Rare Dis Res       Date:  2016-05

7.  Nasal surgery in patients with systemic disorders.

Authors:  Florian Sachse; Wolfgang Stoll
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2011-04-27

8.  Can Iron Treatments Aggravate Epistaxis in Some Patients With Hereditary Hemorrhagic Telangiectasia?

Authors:  Claire L Shovlin; Clare Gilson; Mark Busbridge; Dilip Patel; Chenyang Shi; Roberto Dina; F Naziya Abdulla; Iman Awan
Journal:  Laryngoscope       Date:  2016-04-23       Impact factor: 3.325

9.  Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia.

Authors:  Claire L Shovlin
Journal:  Front Genet       Date:  2015-04-09       Impact factor: 4.599

10.  Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: associations with iron deficiency and platelets.

Authors:  Claire L Shovlin; Basel Chamali; Vatshalan Santhirapala; John A Livesey; Gillian Angus; Richard Manning; Michael A Laffan; John Meek; Hannah C Tighe; James E Jackson
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.